Pacific Edge's Laboratory Throughput Up 0.7% in Fiscal Q3; US Injunction Mulled in Wake of Novitas Decision

MT Newswires Live

Jan 22, 2025

Pacific Edge (NZE:PEB, ASX:PEB) reported total laboratory throughput of 7,092 tests for the fiscal third quarter ended December 2024, a 0.7% rise from the prior three-month period, according to a Wednesday filing with the Australian and New Zealand bourses.

Its sales force efficiency metric was flat at 379 tests per sales of a full-time employee. Tests per unique US ordering clinician was up 9.1% to 7.

The cancer diagnostics company plans to seek a preliminary injunction in the US relating to the removal of its flagship Cxbladder test from the coverage of Medicare contractor, Novitas.

Pacific Edge said this move is "on the basis of the irreparable harm" that Novitas' decision would cause its business if efforts to negotiate a withdrawal or revision fail, per the filing.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2505478035"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2505478035\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2505478035?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-22 05:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2505478035","market":"fut","top_or_hot":-1,"title":"Pacific Edge's Laboratory Throughput Up 0.7% in Fiscal Q3; US Injunction Mulled in Wake of Novitas Decision","media":"MT Newswires Live","content":"<html><body><p> Pacific Edge (NZE:PEB, ASX:PEB) reported total laboratory throughput of 7,092 tests for the fiscal third quarter ended December 2024, a 0.7% rise from the prior three-month period, according to a Wednesday filing with the Australian and New Zealand bourses.</p><p>Its sales force efficiency metric was flat at 379 tests per sales of a full-time employee. Tests per unique US ordering clinician was up 9.1% to 7.</p><p>The cancer diagnostics company plans to seek a preliminary injunction in the US relating to the removal of its flagship Cxbladder test from the coverage of Medicare contractor, Novitas.</p><p>Pacific Edge said this move is \"on the basis of the irreparable harm\" that Novitas' decision would cause its business if efforts to negotiate a withdrawal or revision fail, per the filing.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pacific Edge's Laboratory Throughput Up 0.7% in Fiscal Q3; US Injunction Mulled in Wake of Novitas Decision</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPacific Edge's Laboratory Throughput Up 0.7% in Fiscal Q3; US Injunction Mulled in Wake of Novitas Decision\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-01-22 05:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Pacific Edge (NZE:PEB, ASX:PEB) reported total laboratory throughput of 7,092 tests for the fiscal third quarter ended December 2024, a 0.7% rise from the prior three-month period, according to a Wednesday filing with the Australian and New Zealand bourses.</p><p>Its sales force efficiency metric was flat at 379 tests per sales of a full-time employee. Tests per unique US ordering clinician was up 9.1% to 7.</p><p>The cancer diagnostics company plans to seek a preliminary injunction in the US relating to the removal of its flagship Cxbladder test from the coverage of Medicare contractor, Novitas.</p><p>Pacific Edge said this move is \"on the basis of the irreparable harm\" that Novitas' decision would cause its business if efforts to negotiate a withdrawal or revision fail, per the filing.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PEB.AU","symbol_name":"PACIFIC EDGE LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2505478035","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2505478035","pubTimestamp":1737496102,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Pacific Edge  reported total laboratory throughput of 7,092 tests for the fiscal third quarter ended December 2024, a 0.7% rise from the prior three-month period, according to a Wednesday filing with the Australian and New Zealand bourses.Its sales force efficiency metric was flat at 379 tests per sales of a full-time employee. Tests per unique US ordering clinician was up 9.1% to 7.The cancer diagnostics company plans to seek a preliminary injunction in the US relating to the removal of its flagship Cxbladder test from the coverage of Medicare contractor, Novitas.Pacific Edge said this move is \"on the basis of the irreparable harm\" that Novitas' decision would cause its business if efforts to negotiate a withdrawal or revision fail, per the filing.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PEB.AU":"PACIFIC EDGE LTD","BK7067":"生物科技"},"translate_title":"Pacific Edge第三财季实验室吞吐量增长0.7%；诺维塔斯决定后美国考虑禁令","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PEB.AU":0.9},"content_text":"Pacific Edge (NZE:PEB, ASX:PEB) reported total laboratory throughput of 7,092 tests for the fiscal third quarter ended December 2024, a 0.7% rise from the prior three-month period, according to a Wednesday filing with the Australian and New Zealand bourses.Its sales force efficiency metric was flat at 379 tests per sales of a full-time employee. Tests per unique US ordering clinician was up 9.1% to 7.The cancer diagnostics company plans to seek a preliminary injunction in the US relating to the removal of its flagship Cxbladder test from the coverage of Medicare contractor, Novitas.Pacific Edge said this move is \"on the basis of the irreparable harm\" that Novitas' decision would cause its business if efforts to negotiate a withdrawal or revision fail, per the filing.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}